GlassScriptPhysician profile
Whitney J Beam
NPI 1932713294
$7,100.46
in general payments reported to CMS, 2019-2025
31 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $1,610 · 2023: $2,004 · 2024: $1,573 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,268.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $2,768.74 | 2021-2025 | Omnipod |
| Dexcom, INC. | $865.58 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $774.23 | 2022-2025 | Minimed 780g, Minimed 770g |
| Tandem Diabetes Care, INC. | $565.55 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $322.52 | 2022-2025 | Skytrofa |
| Abbott Laboratories | $321.12 | 2022-2025 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $230.86 | 2023-2025 | Triptodur, Triptodur |
| Xeris Pharmaceuticals, INC. | $221.33 | 2023-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $195.98 | 2023-2025 | |
| Ucb, INC. | $104.19 | 2024-2025 | Briviact, Fintepla |
| Amphastar Pharmaceuticals, INC. | $78.12 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $62.00 | 2022-2024 | Dupixent |
| Alexion Pharmaceuticals, INC. | $57.64 | 2021-2023 | Strensiq |
| Qol Medical, LLC | $50.99 | 2021-2025 | Sucraid |
| 180 Medical, INC. | $49.53 | 2023-2024 | Gentlecath |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $44.52 | 2025 | Fensolvi |
| Novo Nordisk INC | $44.39 | 2023-2025 | Sogroya |
| Soleno Therapeutics, INC. | $39.99 | 2025 | Vykat Xr |
| Nestle Healthcare Nutrition INC. | $39.17 | 2022 | |
| Abbvie INC. | $38.96 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.86 | 2024 | Eohilia |
| Ipsen Biopharmaceuticals, INC | $35.48 | 2024 | Bylvay |
| Eton Pharmaceuticals, INC. | $23.77 | 2025 | Increlex, Alkindi, Khindivi |
| Beta Bionics, INC. | $21.37 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $21.14 | 2025 | Twiist |
| Endo Pharmaceuticals INC. | $20.57 | 2021 | |
| Biomarin Pharmaceutical INC. | $19.83 | 2023 | Voxzogo 1.2mg |
| Amneal Pharmaceuticals LLC | $16.04 | 2023 | Unithroid |
| Phadia US INC. | $14.95 | 2023 | Immunocap |
| Mirum Pharmaceuticals, INC. | $13.55 | 2022 | |
| Travere Therapeutics, INC. | $2.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Beam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.